Summary & Overview
HCPCS J7626: Budesonide Inhalation Solution, DME Unit Dose, up to 0.5 mg
HCPCS Level II code J7626 denotes budesonide inhalation solution, an FDA‑approved, non‑compounded unit‑dose formulation delivered through durable medical equipment (DME) at doses up to 0.5 mg. This code identifies billing for the drug product and its provision via inhalation devices and matters nationally as inhaled corticosteroids are a common, guideline‑directed therapy for chronic respiratory conditions and acute exacerbation management delivered outside inpatient settings. Accurate coding affects claims processing, patient access to DME‑delivered medications, and Medicare and commercial payment workflows.
Key payers covered in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. The publication outlines coverage and reimbursement context relevant to these major national payers.
Readers will learn the clinical and billing context for J7626, the typical site of service and service type, and what to expect in terms of payer coverage framing and coding considerations. The content summarizes available benchmarks where present, notes recent policy or coding clarifications when applicable, and situates the code within standard respiratory care delivery pathways. Data not available in the input will be explicitly noted where relevant.
Billing Code Overview
HCPCS Level II code J7626 describes budesonide inhalation solution, FDA-approved final product, non-compounded, administered through durable medical equipment (DME), unit dose form, up to 0.5 mg. The service is the provision and administration of an inhaled corticosteroid formulation intended for respiratory delivery.
Service Type: Medication administered via DME (inhalation solution, unit dose)
Typical Site of Service: Home or outpatient setting where durable medical equipment is used to deliver inhalation therapy
Clinical & Coding Specifications
Clinical Context
A typical patient is a pediatric or adult with persistent asthma or recurring wheeze who requires administration of inhaled corticosteroid therapy via a nebulizer supplied as a unit-dose solution by durable medical equipment (DME). The patient presents to an outpatient pulmonary clinic, home health nurse visit, or DME supplier consult after diagnosis or exacerbation. The clinician assesses symptoms, peak flow or spirometry as available, and prescribes J7626 (budesonide inhalation solution, unit dose, up to 0.5 mg) to be delivered through the patient’s nebulizer. The DME supplier dispenses FDA-approved, non-compounded unit-dose vials, documents dispensing and match to prescription, and trains the patient or caregiver on administration, frequency, and cleaning of the nebulizer. Billing for J7626 is submitted with the appropriate service and place-of-service codes for DME-supplied medications; clinical documentation includes diagnosis supporting inhaled corticosteroid therapy, prescription details (dose, frequency, duration), and record of patient education and DME delivery.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
00 | No modifier (default) | Use when no special reporting modifier is required. |